These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 578665)

  • 21. [Results of treatment of Graves-Basedow disease with 131I at low calculated doses].
    Gómez Arnaiz N; Gómez Saez JM; Orti Llavería A; Gavaldá Mestre L; Mairal Pairó L; Soler Ramón J
    Rev Clin Esp; 1998 Feb; 198(2):57-60. PubMed ID: 9558917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transient hypothyroidism after iodine-131 treatment of Graves' disease.
    Gómez JM; Virgili N; Soler J; Fernández M; Montaña E
    Thyroidology; 1989 Dec; 1(3):149-52. PubMed ID: 2484879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease.
    Chen JJ; Ladenson PW
    J Clin Endocrinol Metab; 1986 Jul; 63(1):102-6. PubMed ID: 2423547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
    Howarth D; Epstein M; Lan L; Tan P; Booker J
    Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The outcome of adjusted accumulation dose of treatment of Graves' disease].
    Gomi Y; Hamada N; Yoshimura H; Ishikawa N; Momotani N; Ito K; Inoue T; Suzuki S
    Kaku Igaku; 1997 Dec; 34(12):1131-8. PubMed ID: 9494335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Follow-up of compensated low-dose 131I therapy for Graves' disease.
    N Engl J Med; 1984 Dec; 311(25):1635-7. PubMed ID: 6548797
    [No Abstract]   [Full Text] [Related]  

  • 27. [Impact of pretreatment variables on the outcome of standardized 131I therapy with 150 Gray in Graves' disease].
    Pfeilschifter J; Elser H; Haufe S; Ziegler R; Georgi P
    Nuklearmedizin; 1997 Apr; 36(3):81-6. PubMed ID: 9162906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism.
    El Refaei SM; Shawkat W
    Nucl Med Commun; 2008 Jul; 29(7):642-8. PubMed ID: 18528187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up studies on iodine-131 treatment of hyperthyroid Graves' disease based on the measurement of thyroid volume by ultrasonography.
    Tsuruta M; Nagayama Y; Yokoyama N; Izumi M; Nagataki S
    Ann Nucl Med; 1993 Aug; 7(3):193-7. PubMed ID: 8217496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs.
    Esfahani AF; Kakhki VR; Fallahi B; Eftekhari M; Beiki D; Saghari M; Takavar A
    Hell J Nucl Med; 2005; 8(3):158-61. PubMed ID: 16390021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose].
    Bakker SC; Zanin DE; Zweers EJ
    Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1837-41. PubMed ID: 12382370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A five-year follow-up of two different 131I treatment methods for Graves' disease and the factors affecting the outcome].
    Yoshimoto M; Iino S; Yoshimura H; Ishikawa N; Momotani N; Hamada N; Ito K
    Nihon Naibunpi Gakkai Zasshi; 1994 Nov; 70(9):995-1006. PubMed ID: 7851625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in thyroid volume in response to radioactive iodine for Graves' hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome.
    Murakami Y; Takamatsu J; Sakane S; Kuma K; Ohsawa N
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3257-60. PubMed ID: 8784079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
    Franklyn JA; Daykin J; Holder R; Sheppard MC
    QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence of hypothyroidism following small doses of 131I in the treatment of Graves' disease.
    McCullagh EP; Jelden GL; Rodriguez-Antunez A
    Ohio State Med J; 1976 Sep; 72(9):538-40. PubMed ID: 989600
    [No Abstract]   [Full Text] [Related]  

  • 36. Radioiodine-induced hypothyroidism in Graves' disease: factors associated.
    Cunnien AJ; Hay ID; Gorman CA; Offord KP; Scanlon PW
    J Nucl Med; 1982 Nov; 23(11):978-83. PubMed ID: 6897075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discriminant factors affecting early outcome of radioiodine treatment for Graves' disease.
    Kung AW; Choi P; Lam KS; Pun KK; Wang C; Yeung RT
    Clin Radiol; 1990 Jul; 42(1):52-4. PubMed ID: 2390837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
    Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
    Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
    Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relapse of Graves' disease 23 years after treatment with radioactive iodine (131I).
    Hegele RA; Volpé R
    J Clin Lab Immunol; 1985 Oct; 18(2):103-5. PubMed ID: 3841162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.